Table 9 Sensitivity analysis results for a time horizon of 2 years: variation of costs
From: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Costs of diagnostic tests* | Additional tests** versus Aptima, n = | Additional costs versus Aptima, € |
|---|---|---|
Lower value (−25%) | ||
Hybrid Capture® 2 | 262,443 | 305,247,597.53 € |
Cobas® 4800 | 269,856 | 2,238,152.57 € |
Higher value (+ 25%) | ||
Hybrid Capture® 2 | 262,443 | 476,949,371.14 € |
Cobas® 4800 | 269,856 | 3,497,113.38 € |